This suggests that the inhibition of Jmjd3 can be considered as an important therapeutic strategy to alleviate chronic pain by blocking blood-nerve barrier hyperpermeability and neuroinflammation in LSS patients. Here, KDM6B is linked to Leigh syndrome.